Fig. 1From: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancerZilovertamab concentration in plasma of representative patients. Zilovertamab concentration (mcg/mL) is indicated on the y axis, and time (weeks) is indicated on the x axis. Arrows indicate days of infusion of zilovertamabBack to article page